Beyond 1L EGFRm mNSCLC Management: Today’s Challenges, Tomorrow’s Approach
mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC
By
OncoAlert
FEATURING
Charu Aggarwal
By
OncoAlert
FEATURING
Charu Aggarwal
Disclaimer: On February 16, 2024, the FDA approved osimertinib (TAGRISSO®) with platinum-based chemotherapy for patients with la/mNSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Comments 0
Login to view comments.
Click here to Login
